Wave Life Sciences Announces Positive Interim Data from …
WEB1 day ago · About WVE-N531 WVE-N531 is an exon skipping oligonucleotide being developed as a disease modifying treatment for boys with Duchenne muscular dystrophy amenable to exon 53 skipping. WVE-N531 was designed using Wave’s best-in-class oligonucleotide chemistry modifications, including PN backbone chemistry.
Wave Life Sciences Stock Surges On Promising Interim Data From …
WEB13 hours ago · On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 ...
Wave Life Sciences’ WVE-N531 Shows Best-in-Class Potential in …
WEB1 day ago · The positive interim results have led Fein to increase the probability of success for WVE-N531 in the U.S. and to raise the price target from $15 to $22. ... WAVE Life Sciences NewsMORE.
Wave surfs DMD success to regulators' doors, sending stock up
WEB14 hours ago · WVE-N531 contains chemistry that is intended to enable high drug exposure in muscle, the tissue that is at the center of the health challenges faced by people with DMD. Wave reported mean muscle ...
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully …
WEB1 day ago · Although work began on development of WVE-N531 in 2021, investors had little to cheer through 2022 and 2023, and shares began 2024 trading ~$4 per share, down 75% since IPO.
Wave Life Sciences Reports Positive Data From Phase 2 FORWARD …
WEB16 hours ago · In the study, 11 boys amenable to exon 53 skipping are being treated with WVE-N531. Results from the interim analysis of ambulatory boys showed dystrophin expression of 9 percent and mean absolute ...
Wave stock gains on Duchenne therapy data (NASDAQ:WVE)
WEB16 hours ago · Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne muscular dystrophy (DMD). Read more here.
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
WEB16 hours ago · Wave said WVE-N531 showed substantial dystrophin expression and was safe and well tolerated after 24 weeks in a Phase 2 study in boys with Duchenne who are amenable to exon 53 skipping.
FDA gives WVE-N531, exon 53 skipping therapy, supportive status
WEBAug 20, 2024 · The U.S. Food and Drug Administration (FDA) has given WVE-N531, an investigational therapy for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping, a rare pediatric drug designation.
Wave Life Sciences' stock soars 51% after biotech posts positive …
WEB10 hours ago · Wave Life Sciences (WVE) said the trial of its WVE-N531, an exon skipping oligonucleotide being investigated in boys with DMD who are amenable to exon 53 skipping, showed substantial dystrophin ...
- Some results have been removed